Precision Approaches in the Diagnosis and Management of Inflammatory Bowel Disease

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 1354

Editors

Division of Gastroenterology and Hepatology, Stanford Medicine, Stanford University, 300 Pasteur Dr., Palo Alto, CA 94305, USA
Interests: Inflammatory Bowel Disease (IBD); integrating systems biology; microbiome–immune interactions; immunometabolism; dietary and pharmacologic interventions

E-Mail
Guest Editor
Department of Biology, University of British Columbia, Kelowna, BC, Canada
Interests: inflammatory bowel disease; intestinal protection

Special Issue Information

Dear Colleagues,

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic immune-mediated disorder of the gastrointestinal tract, marked by relapsing inflammation, unpredictable symptom patterns, and heterogeneous treatment responses. While current therapies have improved disease control, many patients experience only partial remission or develop treatment-related complications that affect long-term outcomes. In addition to intestinal inflammation, growing evidence highlights the broader systemic impact of IBD and its therapies, including increased risk of metabolic dysfunction, weight gain, insulin resistance, and hepatobiliary disease. These complications not only affect overall health but may also contribute to disease progression. Addressing these challenges requires more integrative and personalized approaches to care. Recent advances in noninvasive diagnostics, microbiome-targeted therapies, dietary interventions, and multi-omics profiling are transforming how we understand and manage IBD. Alongside these, clinical strategies such as therapeutic repurposing, combination treatments, personalized dosing, and biomarker-based decision-making are helping to drive a broader shift toward precision medicine. This Special Issue aims to highlight the latest research in the diagnosis, monitoring, and treatment of IBD, with a focus on individualized, mechanistically guided strategies. We welcome contributions from researchers and clinicians working across disciplines to advance understanding of IBD pathophysiology and improve patient-centered outcomes.

Dr. Jiayu Ye
Dr. Andrea Verdugo-Meza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • ulcerative colitis
  • Crohn’s disease
  • precision medicine
  • microbiome-based therapy
  • noninvasive diagnostics
  • stratified therapeutic response
  • immunometabolism
  • system immunology
  • therapeutic repurposing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 782 KB  
Article
Serum Interleukin-10 as a Potential Biomarker for Deep Remission and Histologic Activity in Ulcerative Colitis
by Nikolaos Martinos, Christos Kroupis, Andreas C. Lazaris and Georgia-Eleni Thomopoulou
Biomedicines 2026, 14(4), 908; https://doi.org/10.3390/biomedicines14040908 - 16 Apr 2026
Viewed by 837
Abstract
Background/Objectives: Deep remission, defined as the coexistence of endoscopic remission and histologic healing, has emerged as an advanced therapeutic target in ulcerative colitis (UC). However, reliable non-invasive biomarkers capable of accurately reflecting histologic inflammatory status remain limited. We aimed to evaluate the association [...] Read more.
Background/Objectives: Deep remission, defined as the coexistence of endoscopic remission and histologic healing, has emerged as an advanced therapeutic target in ulcerative colitis (UC). However, reliable non-invasive biomarkers capable of accurately reflecting histologic inflammatory status remain limited. We aimed to evaluate the association between serum interleukin-10 (IL-10) concentrations and deep remission in UC and to assess its discriminatory performance. Methods: In this prospective single-center observational study, consecutive adult patients with ulcerative colitis undergoing clinically indicated colonoscopy were enrolled. Serum IL-10 concentrations were measured prior to endoscopy using an enzyme-linked immunosorbent assay. Histologic healing was defined as a Geboes score < 2.0, and deep remission as the coexistence of endoscopic remission and histologic healing. Associations were evaluated using Firth penalized logistic regression. Discrimination was assessed using receiver operating characteristic analysis with bootstrap internal validation (500 resamples). Results: Among 44 patients, 18 (40.9%) achieved deep remission. Serum IL-10 levels were significantly higher in patients with histologic healing compared with those with active histologic inflammation (p < 0.001). Log-transformed IL-10 was independently associated with deep remission in both univariable and multivariable models. The primary multivariable model demonstrated apparent good discrimination (apparent AUC 0.88; optimism-corrected AUC 0.85). Among patients in endoscopic remission, non-detectable IL-10 identified persistent histologic activity with high sensitivity (92.9%) and negative predictive value (94.4%), although these findings are exploratory. Conclusions: Serum IL-10 concentrations were independently associated with deep remission and showed potentially promising internally validated discriminatory performance within this cohort. These findings are hypothesis-generating and require external validation in larger cohorts before clinical application. Full article
Show Figures

Graphical abstract

Back to TopTop